How to launch a UK sleep and insomnia telehealth service in 2026: zopiclone, melatonin, and safe remote prescribing

Sleep disorders represent one of the least-served gaps in UK private healthcare. NHS referral waits for sleep assessment stretch to months in many regions, and most patients experiencing chronic insomnia receive no structured treatment at all. For telehealth operators with the right clinical governance in place, this is a viable, in-demand vertical — but one with specific prescribing risks that make it more complex than it looks on paper.

The sleep market opportunity for UK telehealth operators

Chronic insomnia affects a substantial proportion of UK adults, with population surveys consistently placing the figure above one in ten. Most receive no treatment beyond GP advice or over-the-counter antihistamines. NHS specialist sleep services are under-resourced, with waits for polysomnography or CBT-i programmes running into months or longer in many trusts. Private provision has grown, but remains fragmented.

Telehealth closes part of that gap. A well-designed remote service can conduct structured sleep assessment, initiate evidence-based interventions including pharmacotherapy where indicated, and refer on to specialist services when needed. Operators who already run mental health or GP-equivalent platforms will find significant patient overlap — anxiety, depression, and insomnia frequently co-occur — and much of the clinical governance infrastructure transfers across.

What the prescribing landscape looks like

First-line treatment for chronic insomnia in NICE guidance is cognitive behavioural therapy for insomnia (CBT-i). A credible sleep service must offer access to CBT-i — through direct provision, an accredited digital programme, or a clear referral pathway — before defaulting to pharmacotherapy. Prescribing medicines as the opening move is both poor clinical practice and a GPhC concern waiting to surface at inspection.

For pharmacotherapy, the commonly considered options are Z-drugs (principally zopiclone in the UK) and melatonin. Antihistamine-based sleep aids (diphenhydramine and similar) can be discussed as bridging options but are not a sound basis for a clinical service. Where any prescribing falls outside licensed indications, clinicians need to understand the framework — see the guide to licensed, off-label, and Specials medicines in UK telehealth.

Z-drugs: Schedule 4 controlled drug requirements

Zopiclone is classified as a Schedule 4 Part 1 controlled drug under the Misuse of Drugs Regulations 2001, as is zaleplon. This classification has direct operational consequences. Prescriptions must comply with the relevant controlled drug requirements; dispensing pharmacies must maintain a Controlled Drugs Register; and supply quantities need to be clinically justified and documented. GMC prescribing guidance emphasises the lowest effective dose for the shortest clinically necessary period for this drug class.

A private telehealth service should have a documented controlled drug policy covering maximum supply per initial consultation, criteria for repeat prescribing, and circumstances in which supply should be declined or escalated. Z-drugs carry dependence potential and should not be issued on an open-repeat basis. For broader context on how controlled drug rules operate in a remote prescribing environment, see the guide to controlled drugs and remote prescribing in the UK. Prescriber discretion applies to all individual decisions.

Melatonin: prescription-only and age-specific licensing

Melatonin is a prescription-only medicine (POM) in the UK, unlike many other markets. The principal licensed formulation for adults — prolonged-release melatonin (Circadin) — holds a UK marketing authorisation for primary insomnia in patients aged 55 and over. Prescribing it to younger adults is off-label. That does not make it impermissible, but prescribers must document their clinical rationale, and patients must give informed consent for treatment outside the licensed indication.

For most telehealth operators, melatonin represents a lower-risk entry point than Z-drugs: no controlled drug obligations, no dependence risk in the conventional sense, and a less contentious prescribing history. Lower risk is not zero governance, however. Clinicians should assess appropriateness, document the off-label position where applicable, and have a structured follow-up in place. Patients who remain under NHS care may benefit from a formalised shared-care arrangement to support monitoring across both settings.

Designing a safe remote clinical pathway

The central challenge in remote sleep assessment is that you are working without objective sleep data. Specialist services use polysomnography and actigraphy. A telehealth clinician has a structured form and a video screen. That limitation should be designed into the pathway — not papered over with a confident-sounding consultation template.

A robust pathway typically includes a validated pre-consultation questionnaire (the Insomnia Severity Index and the Epworth Sleepiness Scale are established tools), clear exclusion criteria covering suspected obstructive sleep apnoea, parasomnias, shift-work disorder, and significant psychiatric comorbidity, structured consultation templates, and defined escalation routes. Patients who screen positive for OSA must be directed to appropriate investigation rather than managed remotely with pharmacotherapy. All of this should be documented in writing before the service opens to patients. The guide to writing clinical SOPs for a UK telehealth service covers what that documentation needs to include.

The governance failure pattern in remote sleep prescribing is rarely the first prescription — it is the absence of any structured review before the second. A repeat Z-drug supply issued without documented reassessment is the kind of oversight that surfaces in a GPhC inspection.

Operational setup: dispensing, follow-up, and monitoring

Sleep prescribing generates a specific dispensing pattern: short courses, structured reviews, and a proportion of patients who escalate rather than improve. Your dispensing partner needs to be configured for that profile. For Z-drug prescribing in particular, maximum-supply limits applied at the dispensing level act as a backstop for any clinical system failure. Where patients need rapid access — and acute insomnia is often a distressing, urgent presentation — same-day dispensing capability is worth evaluating in your partner selection.

Follow-up cadence is a regulatory pressure point. A reasonable model for Z-drug prescribing is a maximum of two to four weeks' supply at initial issue, with a structured review required before any repeat. Melatonin can carry longer follow-up intervals, but a complete absence of follow-up process is a GPhC concern. Your platform should flag prescriptions that receive no contact after a defined window — this is both a patient safety control and an audit trail element that will be examined at inspection.

How PExpo supports operators launching a sleep service

Launching a sleep vertical involves more regulatory surface area than most operators anticipate. POM classification, potential controlled drug workflows, CBT-i access requirements, mandatory follow-up processes, and documented SOPs all need to be in place before you prescribe at scale. PExpo provides the regulated dispensing and prescribing infrastructure — including controlled drug workflows — that operators need to launch quickly without building compliance from scratch.

Whether you are adding sleep prescribing to an existing clinic or building a standalone service, PExpo handles the dispensing, prescription routing, and documentation layer beneath your clinical team. Talk to the PExpo clinic team about how the platform supports controlled drug prescribing, melatonin workflows, and structured follow-up within a single operator account.

Sleep is a genuine gap in the UK private telehealth market — high demand, under-served by the NHS, and well-suited to remote delivery where the pathway is designed with care. Getting governance right before launch — CBT-i access, controlled drug policies, exclusion criteria, and structured follow-up — is what separates a compliant service from a liability. See also controlled drugs and remote prescribing, mental health telehealth for comorbidity pathway considerations, and clinical SOPs for what your documentation needs to cover.

Frequently asked questions